Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETIC OF PF 06863135, A B CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA

X
Trial Profile

A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETIC OF PF 06863135, A B CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elranatamab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms MAGNETISMM-2
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Dec 2023 Results from pooled analysis of MagnetisMM-1 (NCT03269136) study, the Japan Phase 1 MagnetisMM-2 (NCT04798586) study, MagnetisMM-3 (NCT04649359) study, and a Phase 1/2 MagnetisMM-9 (NCT05014412) study evaluating baseline correlation with key disease biomarkers, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 12 Dec 2023 Results of an exposure-efficacy analysis in patients with relapsed or refractory multiple myeloma from from pooled Magnetismm Studies (MagnetisMM-1, MagnetisMM-2, MagnetisMM-3 and MagnetisMM-9) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Results of pooled analysis from (2 Phase 1 studies MagnetisMM-1, MagnetisMM-2; 1 Phase 1/2 Study MagnetisMM-9; 1 Phase 2 Study MagnetisMM-3 assessing selection and validation of the optimal priming regimen for elranatamab as a 2 step-up priming regimen 12 mg on Day 1, 32 mg on Day 4 with first full dose of 76 mg on Day 8 presented at the 64th American Society of Hematology Annual Meeting and Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top